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Glucocorticoids profoundly influence immune responses, and synthetic glucocorticoids are widely
used clinically for their potent antiinflammatory effects. Endogenousglucocorticoid action ismod-
ulated by the two isozymes of 11-hydroxysteroid dehydrogenase (11-HSD). In vivo, 11-HSD1
catalyzes the reduction of inactive cortisone or 11-dehydrocorticosterone into active cortisol or
corticosterone, respectively, thereby increasing intracellular glucocorticoid levels. 11-HSD2 cat-
alyzes the reverse reaction, inactivating intracellular glucocorticoids. Both enzymes have been
postulated to modulate inflammatory responses. In the K/BxN serum transfer model of arthritis,
11-HSD1-deficient mice showed earlier onset and slower resolution of inflammation than wild-
type controls,with greater exostoses in periarticular bone and, uniquely, ganglion cysts, consistent
with greater inflammation. In contrast, K/BxN serum arthritis was unaffected by 11-HSD2 defi-
ciency. In a distinct model of inflammation, thioglycollate-induced sterile peritonitis, 11-HSD1-
deficientmice hadmore inflammatory cells in the peritoneum, but again 11-HSD2-deficientmice
did not differ from controls. Additionally, compared with control mice, 11-HSD1-deficient mice
showed greater numbers of inflammatory cells in pleural lavages in carrageenan-induced pleurisy
with lung pathology consistent with slower resolution. These data suggest that 11-HSD1 limits
acute inflammation. In contrast, 11-HSD2 plays no role in acute inflammatory responses in mice.
Regulation of local 11-HSD1 expression and/or delivery of substratemay afford a novel approach
for antiinflammatory therapy. (Endocrinology 153: 234–240, 2012)
High doses of exogenous glucocorticoids exert potentantiinflammatory effects and remain an effective
therapy for rheumatoid arthritis and other inflammatory
disorders (1). Physiological variation in endogenous glu-
cocorticoid levels also influences inflammatory responses
butwith both anti- and proinflammatory actions, depend-
ing on context and the target cells involved (2, 3).
Endogenous glucocorticoid action within cells and tis-
sues is modulated by intracellular glucocorticoid me-
tabolism by the two isozymes of 11-hydroxysteroid
dehydrogenase (11-HSD),which interconvert active glu-
cocorticoids (cortisol, corticosterone) and intrinsically in-
ert 11-keto metabolites (cortisone, 11-dehydrocortico-
sterone) (4). In vivo, 11-HSD1 predominantly reactivates
glucocorticoids, amplifying their action (5), whereas 11-
HSD2 inactivates glucocorticoids (6).
11-HSD1 is expressed in immune cells, notably mac-
rophages, dendritic cells, and lymphocytes (7–10), with
enzyme levels dependent on cellular activation state (e.g.
during an inflammatory response) (11). In humans, syno-
vial inflammation in rheumatoid arthritis, but not osteo-
arthritis, is positively associated with cortisone reactiva-
tion, suggesting increased synovial 11-HSD1 activity
(12). 11-HSD1 is expressed in synovialmacrophages and
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fibroblasts of patients with rheumatoid arthritis and is
highly inducedby theproinflammatory cytokines IL-1and
TNF- in the latter cell type (13).Moreover, 11-HSD1 is
induced in cells recruited into the peritoneum during ster-
ile peritonitis (9) and is increased in intestine in both hu-
man and rodent colitis (14, 15). Macrophages from mice
deficient in 11-HSD1 show delayed acquisition of
phagocytic capacity and exaggerated production of IL-6
and other cytokines after activation with lipopolysaccha-
ride (9, 16).
Although 11-HSD2 is not normally expressed in im-
mune cells in either humans or mice (7, 9), 11-HSD2 has
been reported in immune cells in joints of patients with
rheumatoid arthritis (12, 17). The nonselective 11-HSD
inhibitor, glycyrrhetinic acid, exerts antiinflammatory ac-
tivity in rheumatoid arthritis, an effect interpreted as due
to 11-HSD2 inhibition (18). Reciprocal regulation of
11-HSD1 and 11-HSD2 by IL-1 and TNF- has been
reported in several nonimmune tissues (19, 20). It has
therefore been suggested that targeting 11-HSD2may be
an effective treatment in rheumatoid arthritis. However,
the effects of 11-HSD2 deficiency on inflammatory re-
sponses have not been reported. Moreover, 11-HSD1
inhibitors are in clinical trials for metabolic disease and
understanding the role of 11-HSD in arthritis and other
clinically relevant inflammatory conditionsmaybe critical
to their exploitation.
A rheumatoid arthritis-like disease develops spontane-
ously in offspring of KRN-transgenic mice bred with
NOD mice due to circulating anti-glucose-6-phosphate-
isomerase autoantibodies (K/BxN serum) (21). Injection
of K/BxN serum into naivemice reliably and reproducibly
induces a self-resolving passive arthritis in recipient mice
(22).Herewehaveusedmicedeficient in either11-HSD1
(23) or 11-HSD2 (24) to investigate the role of these
enzymes in K/BxN serum-induced inflammatory arthritis
and other mouse models of inflammation.
Materials and Methods
Animals
Mice homozygous for a targeted disruption of the Hsd11b1
gene (Hsd11b1/) or the Hsd11b2 gene (Hsd11b2/), both
congenic on the C57BL/6J background (more than eight back-
crosses), have been previously described (23–25). Controls were
age-matched C57BL/6J mice. All experimental mice were males,
aged 8–12 wk, housed in groups of two to five mice per cage
under controlled conditions (12 h light, 12 h dark cycle, 21 C)
with ad libitum access to water and standard rodent chow. All
experimentation was conducted in strict accord with accepted
standards of humane animal care under the auspices of the U.K.
Animals (Scientific Procedures) Act, 1986, after the prior ap-
proval by the local ethical committee.
Induction and assessment of inflammatory
arthritis
Mice were injected ip with arthritic K/BxN serum, generated
in-house fromK/BxNmice [mice expressing the transgenic T cell
FIG. 1. 11-HSD1 deficiency worsens arthritis in mice. K/BxN arthritis
was induced in Hsd11b1/ (white squares, white bar) and control
mice (black squares, black bar) by ip injection of arthritogenic K/BxN
serum, using a standard dose of 7.5 l/g body weight on d 0 and d 2
(A) and a reduced dose of 5.6 l/g body weight on d 0 only (B).
Clinical score (based on edema and redness of carpal and hock joints)
was measured over 21 d. Insets show AUC. Data are mean  SD (n 
5/group), P  0.05 by repeated-measures ANOVA or (for AUC) by
unpaired Student’s t test. *, P  0.05.
FIG. 2. 11-HSD2-deficiency has no effect on K/BxN arthritis in mice.
K/BxN arthritis was induced in Hsd11b2/ (white squares, white bar)
and control mice (black squares, black bar) by a single ip injection of
arthritogenic K/BxN serum (5.6 l/g body weight) on d 0. Clinical score
was measured over 21 d. Inset shows AUC. Data are mean  SD (n 
7–8/group); P  0.96 by repeated-measures ANOVA or (for AUC) by
unpaired Student’s t test; P  0.69.
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receptor KRN and the MHC class II allele Ag7] as previously
described (26) using either the standard dose (7.5 l/g of body
weight on d 0 and d 2) or a reduced dose (single injection of 5.6
l/g of body weight on d 0). The standard dose produces a max-
imal response in controlmice; thus, the reduced dosewas used to
test the hypothesis that the inflammatory response would be
greater inHsd11b1/mice. Inflammationwas scored by visual
examinationaccording to a clinical index inwhich each jointwas
assigned a score of 0–3 as described (38). The mean cumulative
scores were calculated (maximum score per animal of 12) for
each group. Right tarsal joint swelling was measured using a
caliper (Kroeplin POCO-2T;WessexMetrology, Poole,UK) and
was defined as the cumulative difference in joint diameter (mil-
limeters) after induction of arthritis from that measured at the
start of the experiment, reported as mean area under the curve
(AUC) per group. For histology, joints were fixed in 10% for-
malin, decalcified in 10% EDTA in neutral buffered formalin,
and paraffin embedded. Deparaffinized and hydrated joint sec-
tions (4 m) were stained with hematoxylin and eosin for his-
topathological examination.
Corticosterone RIA
Peripheral blood was collected from Hsd11b1/ and wild-
type mice 2 d and 21 d after induction of K/BxN arthritis under
nonstressed conditions by tail nick at 0800 h for measurement
of circulating corticosterone by RIA as described previously
(27).
Thioglycollate-induced sterile peritonitis
Peritonitis was induced in mice by ip injection of 1 ml of 3%
thioglycollate as previously described (9). Peritoneal cells were
collected by lavage with 5 ml cold PBS and counted by
hemocytometer.
Carrageenan-induced pleurisy
Pleural inflammation was induced in mice by intrapleural
injection of 100 l of 0.1% -carrageenan
(Marine Colloids Inc., FMC BioPolymer,
Philadelphia, PA) as previously described
(28). The pleural exudateswere collected by
lavagewith1ml coldPBScontaining3.15%
sodium citrate and recovered cells counted
by hemocytometer. The thoraxwas fixed in
10% formalin, paraffin embedded, and he-
matoxylin and eosin (H&E) staining was
performed on 4- to 5-m sections.
Statistics
The effects of genotype and treatment
were assessed by two-factor, repeated-mea-
sures ANOVA followed by post hoc Bon-
ferroni tests. A Student’s t test was used for
comparisons between genotypes. Signifi-
cance was set at P  0.05. Values are
means  SEM.
Results
11-HSD1 deficiency, but not 11-
HSD2 deficiency, worsens the
course of experimental arthritis
Inflammatory arthritis was induced
in all mice after injection of arthrito-
genic K/BxN serum, whether at the
standarddose (Fig. 1A) or the submaxi-
mal (37% of the standard) dose (Figs.
1B and 2). However, in Hsd11b1/
mice, the onset of inflammation was
earlier than in wild-type controls, irre-
spective of dose, and resolutionwas im-
paired,producingagreaterAUCfor the
clinical score of inflammation (Fig. 1).
Cumulative joint swelling (measured as
joint thickness) induced by the stan-
FIG. 3. Greater exostosis and inflammatory ganglion cysts in Hsd11b1/ mice but not in
Hsd11b2/ mice, after arthritis. Representative images of H&E sections, showing left carpal
joint (top panels) and left tarsal joint (bottom panels) from the following: A, Hsd11b1/ mice
(right panels) vs. control mice (left panels) and B, Hsd11b2/ (right panels) vs. control mice
(left panels). Joints were collected 21 d after induction of experimental arthritis with K/BxN
serum (single injection of 5.6 l/g body weight on d 0) (n  5–8/genotype). Images captured
at 50 magnification. R, Anterior distal radius; U, anterior ulna; G, inflammatory ganglion
cyst; X, exostosis.
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dard dose of K/BxN serum was also greater in
Hsd11b1/ than in controlmice (Hsd11b1/, 8.50.4
mm AUC vs. controls, 6.9  1.1 mm AUC, P  0.05).
Plasma corticosterone levels were elevated to a similar ex-
tent in Hsd11b1/ and control mice 2 d after K/BxN
serum injection (Hsd11b1/, 218  61 nM vs. controls,
253  39 nM), showing that inadequate hypothalamic-
pituitary-adrenal (HPA) axis activation does not underlie
the exacerbated acute inflammation at 2 d. However, at
21 d (when inflammation had resolved in control mice),
although plasma corticosterone levels had reduced in
control mice, they remained elevated inHsd11b1/mice
(Hsd11b1/, 22776nMvs. controls, 8627nM).This
latter finding suggests the persistent activation of theHPA
axis in Hsd11b1/ mice, plausibly due to the ongoing
inflammation because the negative feedback by cortico-
sterone on theHPAaxis inHsd11b1/mice is normal on
the C57BL/6 strain background (29).
In contrast, there was no difference in the clinical score
of inflammation between Hsd11b2/ and control mice
during the course of the inflammatory arthritis, with a
similar AUC for both genotypes (Fig. 2). These data sug-
gest that 11-HSD1 limits joint inflammation in vivo,
whereas 11-HSD2 has no effect on the development or
progression of K/BxN arthritis.
11-HSD1 deficiency, but not 11-HSD2 deficiency,
worsens joint histopathology
After inflammatory arthritis (21 d after injection of
K/BxNserum,when the clinical signs of inflammationhad
largely subsided), carpal joints from all mice showed peri-
articular inflammation, capsular thickening, tenosynovi-
tis, and exostoses of distal radius and ulna and proximal
metacarpals (Fig. 3). Joints of Hsd11b1/ mice, how-
ever, hadmore exuberant and extensive exostoses, greater
periarticular fibrosis, and, uniquely, ganglion cyst forma-
tion, suggestive of more severe inflammation (Fig. 3). In
contrast, there was no histopathological difference be-
tween the joints ofHsd11b2/mice and controls (Fig. 3).
11-HSD1 deficiency, but not 11-HSD2-deficiency,
results in greater inflammation during sterile
peritonitis
After ip injection of thioglycollate to induce sterile peri-
tonitis, Hsd11b1/ mice had more inflammatory cells
within the peritoneum (Fig. 4A). However, despite the
increase in inflammatory cells, there was no difference
in resolution of thioglycollate-induced peritonitis in
Hsd11b1/ mice (data not shown), consistent with pre-
vious data (9). In contrast, inflammatory cell number
within the peritoneum was similar in Hsd11b2/ and
control mice (Fig. 4B), with no difference in resolution,
suggesting that inflammation was normal in this model.
11-HSD1 deficiency results in greater recruitment
of inflammatory cells and more severe pathology
in carrageenan-induced pleural inflammation
The antiinflammatory effects of 11-HSD1 were con-
firmed in another model of inflammation, carageenan-
induced pleurisy, inwhich both inflammatory cell number
and resulting pathology can be assessed within a single
model. Similar to sterile peritonitis, more inflammatory
cells were recovered fromHsd11b1/mice than control
mice 4 h and 24 h after intrapleural injection of carra-
FIG. 4. Greater inflammation in Hsd11b1/ mice, but not in
Hsd11b2/ mice, during sterile thioglycollate-induced peritonitis.
Peritonitis was induced in Hsd11b1/ (white bars) and control mice
(black bars) (A) and in Hsd11b2/ (white bars) and control mice (black
bars) (B) by ip injection of 1 ml 3% thioglycollate. Twenty-four hours
later, cells were lavaged (with 5 ml PBS) and counted. Data are
mean  SEM, expressed as cells per milliliter (n  5–8/group); *, P 
0.05 by unpaired Student’s t test.
FIG. 5. Greater inflammation in Hsd11b1/ mice during
carrageenan-induced pleurisy. Pleurisy was induced in Hsd11b1/
(white bars) and control (black bars) mice by intrapleural injection of
100 l 0.1% carrageenan. Four, 24, and 48 h later, cells were lavaged
(with 1 ml PBS) and counted. Results are mean  SD, expressed as cells
per milliliter (n  7/group); **, P  0.01 by two-way ANOVA.
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geenan (Fig. 5). Edema (assessed byweighing the collected
lavages) did not differ between genotypes at either time
point (data not shown). Histological assessment showed
that 48 h after injection of carrageenan, inflammation in
control mice was resolving yet was still in progress in
Hsd11b1/mice,withpersistence of inflammation in the
visceral pleura, the presence of lymphoid aggregates (com-
prisedof plasma cells, lymphocytes, neutrophils, andmac-
rophages) within the lung and periesophageal mediasti-
num, and, uniquely in Hsd11b1/ mice, formation of
fibrous adhesions between lung lobes 48 h after initiation
of pleurisy (Fig. 6). No differences in lung histology were
found between untreated mice (data not shown).
Discussion
Mice deficient in 11-HSD1 showed worse inflammation
in three different experimental models, with impaired res-
olution in two. In contrast, 11-HSD2
deficiency had no effect on inflamma-
tion in either arthritis or peritonitis.
11-HSD1 clearly plays a role in re-
straining the initial inflammatory re-
sponse because greater inflammatory
cell number was seen in 11-HSD1-
deficientmice in both pleurisy and peri-
tonitis, and clinical signs of arthritic in-
flammation were visible in these mice a
full day before control mice. Why the
acute response is worse in these mice is
currently unclear but could be due to
increased recruitment of inflammatory
cells or decreased clearance. The latter
is supported by our previous finding of
a delay in vivo in acquisition of macro-
phagephagocytic capacity inHsd11b1/
mice (9). In both the arthritis and the
pleurisy models of inflammation,
Hsd11b1/ mice showed worse pa-
thology. This could simply reflect the
greater number of inflammatory cells
present during inflammation in these
mice (causing greater tissue damage) or
may additionally reflect an altered tissue
response to inflammation. Proinflamma-
tory cytokines induce11-HSD1expres-
sion in synovial fibroblasts (13) in which
locally amplified glucocorticoid action is
likely to influence both the response of
fibroblasts to inflammation and the local
inflammatory environment that prevails
during the course of arthritis.Whether a similar inductionof
11-HSD1 in pleural and lung fibroblasts dampens local
proinflammatory responses and reduces inflammatory cell
number in pleurisy in controlmice remains to be determined
but is plausible.
In the case of bone, the role of endogenous glucocor-
ticoid metabolism here, particularly during an inflamma-
tory response, is likely to be complex, as demonstrated by
theprotective effectof transgenic11-HSD2expression in
osteoblasts in theK/BxN serum-transfermodel of arthritis
(30, 31). The increased exostosis seen here in the joints of
Hsd11b1/mice suggest altered bone turnover and/or
increased bone synthesis as a response to the local pro-
inflammatory environment [because basal bone archi-
tecture is unaltered in this model (32]. The delay in the
resolution of arthritis in Hsd11b1/ mice may be due
to lack of activity of this enzyme in osteoblasts or may
reflect a normal response to the greater initial inflam-
mation in Hsd11b1/ mice.
FIG. 6. Ongoing inflammation in Hsd11b1/ mice 48 h after carrageenan injection.
Representative images of H&E-stained sections of lungs from Hsd11b1/ and control mice
48 h after intrapleural injection of carrageenan (100 l of 0.1% carrageenan) showing, more
pronounced lymphoid aggregates (A), persistent thickening of visceral pleura (B), and more
aggressive adhesion of lung lobes (C) in Hsd11b1/ than in control mice. Images captured at
50 (A and B) and 500 (C) magnification. LA, Lymphoid aggregates; VP, visceral pleura; A,
adhesions.
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Licorice and its active ingredients such as glycyrrhetinic
acid are nonselective but potent 11-HSD inhibitors that
have long been known to exhibit antiinflammatory activ-
ity, including in rheumatoid arthritis (18). Whether this is
due to increased plasma half-life of cortisol because of
inhibition of renal 11-HSD2-mediated clearance of glu-
cocorticoids (33) or a direct intracrine effect on 11-HSD
activity at the site of inflammation is unclear. Our data do
not suggest a direct effect of 11-HSD2 deficiency on
acute inflammation. Indeed, in contrast to 11-HSD1, ex-
pression of 11-HSD2 is down-regulated by proinflam-
matory cytokines (34, 35), inconsistent with any major
role in the response to inflammation. Moreover, 11-
HSD2 is not expressed in mouse immune cells (11) or in
human leukocytes (7). However, a caveat is raised by re-
ports of 11-HSD2 in synovial macrophages in rheuma-
toid arthritis, and it is possible that the chronic inflam-
matory environment with persistent disease may induce
11-HSD2. It also remains possible that the renal pheno-
type of Hsd11b2/ mice (hypertension, hypokalaemia,
and hypernatraemia) compensates in some way an effect
on inflammation, although it is difficult to envisage how
this might come about.
Inhibition of 11-HSD1, thus reducing intracellular
glucocorticoid levels, shows promise as a drug target for
treatment of metabolic disease, including type 2 diabetes
mellitus (36). Our data suggest that caution should be
exercised in the use of these inhibitors because they may
worsen acute inflammation. Understanding how 11-
HSD1 deficiency exacerbates acute inflammation yet is
protective against the low-grade inflammation associated
with metabolic disease [Hsd11b1/ mice show reduced
inflammation in adipose tissue in obesity (37)] will be crit-
ical in the optimization of emerging therapies for meta-
bolic disease.Moreover, itmight facilitate development of
new antiinflammatory therapies, for example, encapsu-
lated delivery of cortisone to the site of inflammation to
take advantage of local 11-HSD1 activity to generate
cortisolwithin the tissue inwhich itwill be ofmost benefit,
thus limiting the adverse metabolic effects of whole-body
exposure to exogenous synthetic glucocorticoids.
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